The companies plan to combine Haselmeier’s subcutaneous injection technology with Common Sensing’s Gocap injector monitor. The product, which will be sold by Haselmeier, will record the time and dose of every injection and other information, like storage temperature, according to the companies.
“There is a high need to provide patients the means to better monitor the efficacy of their therapy and the injection experience is a crucial moment in a patient’s therapy. The collaboration of Haselmeier with Common Sensing is a smart and fast way to achieve our objective in improving patients’ lives,” Frédéric Gabriel, Haselmeier’s chief strategy officer, said.
Users, caretakers and clinicians will have access to the data collected by the Gocap monitor, Haselmeier reported.
“Haselmeier is excited about the collaboration with Common Sensing. Both companies have recognized how complementary their technologies were and how much this partnership will provide value for both companies and patients. The joint relationship we have built will enable Haselmeier and Common Sensing to rapidly bring a unique connected pen solution on the market,” Paul Jansen, senior advisor and board member, said in prepared remarks.
“This partnership is a fantastic, market shaping opportunity to merge the leading edge, Haselmeier D-Flex injector with our Gocap connected health technology in a scalable, commercial platform,” Kevin Schmid, chief operating officer at Common Sensing, added.